CONSENSUS CONFERENCE ON PLATELET TRANSFUSION, ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 27–28 NOVEMBER 1997: Synopsis of background papers

Dr, Norfolk; Pj, Ancliffe; Contreras, Marcela; Bj, Hunt; Machin, SJ; Wg, Murphy; Lm, Williamson

doi:10.1046/j.1365-2141.1998.00773.x

Cited by 117 publications

(44 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies in solid tumours suggest that this threshold may be acceptable, as the incidence of chemotherapy-induced thrombocytopenia remains low and at-risk patients are readily identifiable [3]. Moreover, the efficacy of such transfusions is reportedly limited [3], as seen in our patient. For patients who are refractory to platelet transfusions, HLA alloimmunisation is the commonest cause, and HLA-matched platelets have been shown to improve platelet increments when transfused, compared with unmatched platelets [4].…”

Section: Discussionmentioning

confidence: 81%

“…In general, guidelines are extrapolated from available data in haematological malignancies [2] and the threshold of 20,000 platelets/μl before administration of prophylactic platelet transfusions is widely used [2]. Recent studies in solid tumours suggest that this threshold may be acceptable, as the incidence of chemotherapy-induced thrombocytopenia remains low and at-risk patients are readily identifiable [3]. Moreover, the efficacy of such transfusions is reportedly limited [3], as seen in our patient.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

‘Pseudo Wine Glass’ Radiological Appearance of Intracranial Haemorrhage as a Result of Chemotherapy-Induced Thrombocytopenia and Red Cell Sedimentation

Oladipo¹,

Kennedy²,

Shiels

et al. 2010

Case Rep Oncol

View full text Add to dashboard Cite

The radiological features of intracranial haemorrhage are well described in the literature, but atypical appearances can sometimes develop. We report a case of chemotherapy-induced thrombocytopenia resulting in fatal intracranial haemorrhage in a man undergoing autologous peripheral stem cell transplantation. The CT showed an unusual appearance, with separation of blood products and fluid within the haemorrhage leading to a wine-glass-shaped outline in the image. This case draws attention to this uncommon radiological finding and emphasises the risks of allosensitisation following chemotherapy and peripheral stem cell transplantation.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

‘Pseudo Wine Glass’ Radiological Appearance of Intracranial Haemorrhage as a Result of Chemotherapy-Induced Thrombocytopenia and Red Cell Sedimentation

Oladipo¹,

Kennedy²,

Shiels

et al. 2010

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“…Controversy persists as to the threshold platelet level at which to transfuse the non-bleeding patient undergoing invasive procedure as well as the optimal dose of platelets to use. There is a general consensus, however, that between a platelet level of 10 and 50000µl, there is increased bleeding risk during haemostasis challenge 7. Hence, in the light of our patient's baseline platelet count of 33000µl, we decided that he should undergo platelet transfusion to achieve adequate haemostasis when the arterial sheath was removed after the procedure.…”

Section: Discussionmentioning

confidence: 95%

Coronary artery stenting in a patient with chronic immune thrombocytopenic purpura: a clinical conundrum

2012

View full text Add to dashboard Cite

SummaryA patient with long-standing immune thrombocytopenic purpura (ITP) would logically contradict antiplatelet use due to increased bleeding risk during coronary stenting. Coronary stenting using an endothelial progenitor cells (EPC) capture stents (Genous TM ) was used to successfully revascularise our patient using a transradial approach. The only complication was extensive superficial ecchymosis on the patient's forearm from antiplatelet use, which resolved spontaneously. To the best of our knowledge, this is the first case report of EPC capture stents in a chronic ITP patient. BACKGROUND

show abstract

“…Platelet transfusion is generally reserved for patients with impaired marrow production of platelets, is rarely needed in patients with increased platelet destruction such as autoimmune or drug-associated immune thrombocytopenia, and is relatively contraindicated in patients with thrombotic thrombocytopenic purpura because of concerns about the risk of precipitating thromboses. 46,47 Gmür and Schaffner 48 reported that their protocol could also be applied using random-donor platelets rather than single-donor, apheresis platelets.…”

Section: Conflict Of Interestmentioning

confidence: 99%

“…Thus, although there are no contemporary randomized studies comparing the incidence of serious bleeding and patient survival in patients receiving prophylactic versus therapeutic platelet transfusions, the prophylactic approach has become standard practice. 45,46,47 Fatal hemorrhage is now an unusual event, even in patients with bone marrow failure or in those receiving intensive antineoplastic therapy. However, it should be emphasized that not all thrombocytopenic patients require or benefit from platelet transfusion and that the decision to administer transfusion is not based solely on the platelet count but should be individualized for specific clinical settings, as discussed below.…”

Section: Conflict Of Interestmentioning

confidence: 99%

Platelet Transfusion Therapy

Karim

Hoque²,

Hoque

et al. 2017

Anwer Khan Mod Med Coll J

View full text Add to dashboard Cite

Patients with severe thrombocytopenia are presumed to be at increased risk for bleeding, and consequently it has been standard practice for the past four decades to give allogeneic platelet transfusions to severely thrombocytopenic patients as supportive care. Platelet transfusions may be given either prophylactically to reduce the risk of bleeding, in the absence of clinical hemorrhage (prophylactic transfusions), or to control active bleeding when present (therapeutic transfusions). Platelets for transfusion can be prepared either by separation of units of platelet concentrates (PCs) from whole blood, which are pooled before administration, or by apheresis from single donors. Comparative studies have shown that the post transfusion increments, hemostatic benefit, and side effects are similar with either product. Thus, in routine circumstances, they can be used interchangeably. In most centers, pooled PCs are less costly. Single-donor platelets from selected donors are preferred when histocompatible platelet transfusions are needed. Both preparations can be stored for up to 5 days after collection at 20°C to 24°C with good maintenance of platelet viability. It is now uncommon for patients undergoing intensive chemotherapy or bone marrow transplantation to die of hemorrhage, but it is open to debate as to what degree platelet transfusions have been responsible for this change in outcome, given the many other advances in other aspects of supportive care.Anwer Khan Modern Medical College Journal Vol. 6, No. 2: July 2015, P 40-46

show abstract

CONSENSUS CONFERENCE ON PLATELET TRANSFUSION, ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 27–28 NOVEMBER 1997: Synopsis of background papers

Cited by 117 publications

References 51 publications

‘Pseudo Wine Glass’ Radiological Appearance of Intracranial Haemorrhage as a Result of Chemotherapy-Induced Thrombocytopenia and Red Cell Sedimentation

‘Pseudo Wine Glass’ Radiological Appearance of Intracranial Haemorrhage as a Result of Chemotherapy-Induced Thrombocytopenia and Red Cell Sedimentation

Coronary artery stenting in a patient with chronic immune thrombocytopenic purpura: a clinical conundrum

Platelet Transfusion Therapy

Contact Info

Product

Resources

About